Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells
暂无分享,去创建一个
F. C. Santos | S Van Segbroeck | J M Pacheco | D. Dingli | S. Van Segbroeck | F. A. Chalub | D Dingli | Fabio A. C. C. Chalub | F A C C Chalub | F C Santos | J. M. Pacheco | S. V. Segbroeck
[1] Arne Traulsen,et al. Multiple mutant clones in blood rarely coexist. , 2008, Physical review. E, Statistical, nonlinear, and soft matter physics.
[2] K. Moriyama,et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. , 2004, Blood.
[3] A. Dispenzieri,et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1{beta}-induced interleukin 6 production and the myeloma proliferative component. , 2009, Mayo Clinic proceedings.
[4] C. Dinarello,et al. Immunological and inflammatory functions of the interleukin-1 family. , 2009, Annual review of immunology.
[5] Josef Hofbauer,et al. Evolutionary Games and Population Dynamics , 1998 .
[6] C. Dinarello. Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease. , 2009, Mayo Clinic proceedings.
[7] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[8] G. Roodman,et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. , 2001, The Journal of clinical investigation.
[9] J M Smith,et al. Evolution and the theory of games , 1976 .
[10] Arne Traulsen,et al. On the Origin of Multiple Mutant Clones in Paroxysmal Nocturnal Hemoglobinuria , 2007, Stem cells.
[11] O. Cope,et al. Multiple myeloma. , 1948, The New England journal of medicine.
[12] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[13] I. Tomlinson,et al. Game-theory models of interactions between tumour cells. , 1997, European journal of cancer.
[14] B. Barlogie,et al. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. , 2008, Bone.
[15] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[16] 北村 聖. "The New England Journal of Medicine". , 1962, British medical journal.
[17] R. Bataille,et al. Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.
[18] D. Jelinek,et al. Mechanisms of myeloma cell growth control. , 1999, Hematology/oncology clinics of North America.
[19] T. Weber,et al. SECONDARY OSTEOPOROSIS : Diagnostic Considerations , 1998 .
[20] E. Terpos,et al. New insights into the pathophysiology and management of bone disease in multiple myeloma , 2003, British journal of haematology.
[21] Toshio Matsumoto,et al. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)‐1α and MIP‐1β correlates with lytic bone lesions in patients with multiple myeloma , 2004, British journal of haematology.
[22] M. Dimopoulos,et al. Myeloma bone disease and proteasome inhibition therapies. , 2007, Blood.
[23] J. Epstein,et al. Consequences of interactions between the bone marrow stroma and myeloma. , 2003, The hematology journal : the official journal of the European Haematology Association.
[24] Bart Barlogie,et al. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. , 2007, Blood.
[25] W. F. Bodmer,et al. Modelling the consequences of interactions between tumour cells. , 1997, British Journal of Cancer.
[26] G. Roodman. Pathogenesis of myeloma bone disease , 2009, Leukemia.
[27] X. Mariette,et al. The High Rate of Bone Resorption in Multiple Myeloma is due to RANK (Receptor Activator of Nuclear Factor-κB) and RANK Ligand Expression , 2004, Leukemia & lymphoma.
[28] J. Berenson. Bone disease in myeloma , 2001, Current treatment options in oncology.
[29] Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth. , 2008, Blood.
[30] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[31] K. Vanderkerken,et al. The role of the bone marrow microenvironment in multiple myeloma. , 2005, Histology and histopathology.
[32] O. Stephens,et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. , 2008, Blood.
[33] I. Holen,et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. , 2001, Blood.
[34] K. Pienta,et al. Evolution of cooperation among tumor cells , 2006, Proceedings of the National Academy of Sciences.
[35] P. L. Bergsagel,et al. Multiple myeloma: evolving genetic events and host interactions , 2002, Nature Reviews Cancer.
[36] G. Roodman,et al. Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease , 2001 .
[37] D. Dingli,et al. In vivo and in silico studies on single versus multiple transplants for multiple myeloma , 2007, Cancer science.
[38] J. Rossi,et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. , 1996, The New England journal of medicine.
[39] J. Crowley,et al. International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] P. L. Bergsagel,et al. Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] D. Dingli,et al. Serum M‐spike and transplant outcome in patients with multiple myeloma , 2007, Cancer science.
[42] R. Kyle,et al. Drug therapy: Multiple myeloma , 2004 .